Zhiqiang Qin
Concepts (508)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Herpesvirus 8, Human | 46 | 2025 | 98 | 20.090 |
Why?
| | Sarcoma, Kaposi | 28 | 2025 | 76 | 12.160 |
Why?
| | Lymphoma, Primary Effusion | 13 | 2025 | 20 | 6.400 |
Why?
| | Virus Activation | 9 | 2025 | 39 | 4.100 |
Why?
| | Coinfection | 6 | 2025 | 44 | 3.700 |
Why?
| | Endogenous Retroviruses | 4 | 2024 | 7 | 3.210 |
Why?
| | Host-Pathogen Interactions | 8 | 2020 | 144 | 2.170 |
Why?
| | Oncogenic Viruses | 4 | 2021 | 17 | 2.020 |
Why?
| | MicroRNAs | 12 | 2020 | 387 | 1.920 |
Why?
| | Pyridines | 5 | 2018 | 133 | 1.900 |
Why?
| | Schistosomiasis japonica | 5 | 2023 | 5 | 1.890 |
Why?
| | Mouth | 4 | 2020 | 33 | 1.840 |
Why?
| | Humans | 100 | 2025 | 52336 | 1.840 |
Why?
| | Herpesviridae Infections | 7 | 2025 | 57 | 1.810 |
Why?
| | Cell Line, Tumor | 21 | 2025 | 1436 | 1.790 |
Why?
| | Gene Expression Regulation, Neoplastic | 11 | 2021 | 858 | 1.780 |
Why?
| | Viral Proteins | 8 | 2021 | 164 | 1.770 |
Why?
| | Virus Latency | 9 | 2025 | 53 | 1.740 |
Why?
| | Phosphotransferases (Alcohol Group Acceptor) | 5 | 2018 | 22 | 1.700 |
Why?
| | Gene Expression Regulation, Viral | 9 | 2020 | 49 | 1.630 |
Why?
| | HIV Infections | 6 | 2020 | 388 | 1.610 |
Why?
| | Lung Neoplasms | 6 | 2022 | 636 | 1.580 |
Why?
| | Staphylococcus epidermidis | 6 | 2012 | 18 | 1.570 |
Why?
| | Adamantane | 4 | 2018 | 24 | 1.570 |
Why?
| | Signal Transduction | 14 | 2022 | 1716 | 1.540 |
Why?
| | Apoptosis | 17 | 2025 | 1127 | 1.540 |
Why?
| | Gene Expression Regulation | 7 | 2019 | 1006 | 1.510 |
Why?
| | Ceramides | 4 | 2020 | 34 | 1.500 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 5 | 2021 | 170 | 1.460 |
Why?
| | Schistosomiasis | 3 | 2025 | 5 | 1.420 |
Why?
| | Animals | 41 | 2025 | 13523 | 1.400 |
Why?
| | Biofilms | 6 | 2012 | 190 | 1.390 |
Why?
| | Cell Proliferation | 16 | 2025 | 1029 | 1.310 |
Why?
| | Neoplasms | 3 | 2024 | 1305 | 1.280 |
Why?
| | Amino Acid Transport System y+ | 3 | 2015 | 3 | 1.260 |
Why?
| | Autoantibodies | 4 | 2023 | 121 | 1.240 |
Why?
| | Antiviral Agents | 2 | 2021 | 177 | 1.230 |
Why?
| | Papillomavirus Infections | 2 | 2024 | 172 | 1.210 |
Why?
| | Lymphoma | 3 | 2019 | 71 | 1.200 |
Why?
| | Proto-Oncogene Proteins c-met | 3 | 2017 | 19 | 1.160 |
Why?
| | Mice | 24 | 2025 | 5965 | 1.140 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2024 | 299 | 1.130 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2025 | 222 | 1.100 |
Why?
| | Bacterial Proteins | 4 | 2020 | 361 | 1.100 |
Why?
| | Interleukin-1 | 2 | 2025 | 108 | 1.080 |
Why?
| | Schistosoma japonicum | 4 | 2023 | 4 | 1.060 |
Why?
| | Gene Expression Profiling | 9 | 2025 | 1110 | 0.990 |
Why?
| | Schistosoma | 1 | 2025 | 1 | 0.980 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2025 | 19 | 0.960 |
Why?
| | Epstein-Barr Virus Infections | 3 | 2022 | 33 | 0.950 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2025 | 35 | 0.940 |
Why?
| | Quinolones | 4 | 2024 | 50 | 0.940 |
Why?
| | Antineoplastic Agents | 4 | 2025 | 1222 | 0.920 |
Why?
| | Cell Transformation, Viral | 2 | 2016 | 25 | 0.920 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2025 | 39 | 0.910 |
Why?
| | Interleukin-10 | 2 | 2018 | 84 | 0.900 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2019 | 165 | 0.900 |
Why?
| | Biological Therapy | 1 | 2024 | 16 | 0.880 |
Why?
| | Histamine | 2 | 2023 | 25 | 0.860 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.860 |
Why?
| | Anus Neoplasms | 1 | 2024 | 25 | 0.850 |
Why?
| | Eukaryotic Initiation Factor-4G | 2 | 2021 | 5 | 0.840 |
Why?
| | Virus Replication | 6 | 2025 | 150 | 0.840 |
Why?
| | Echinomycin | 1 | 2023 | 6 | 0.830 |
Why?
| | Virus Diseases | 1 | 2024 | 45 | 0.830 |
Why?
| | Penile Neoplasms | 1 | 2024 | 44 | 0.830 |
Why?
| | Cough | 1 | 2023 | 55 | 0.830 |
Why?
| | Interferon Type I | 1 | 2023 | 28 | 0.810 |
Why?
| | Herpesviridae | 2 | 2022 | 19 | 0.810 |
Why?
| | Nuclear Proteins | 5 | 2023 | 251 | 0.780 |
Why?
| | Mycoses | 1 | 2023 | 152 | 0.780 |
Why?
| | Porphyromonas gingivalis | 2 | 2020 | 17 | 0.770 |
Why?
| | Human Umbilical Vein Endothelial Cells | 4 | 2019 | 102 | 0.770 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2022 | 30 | 0.740 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 255 | 0.740 |
Why?
| | Antigens, Helminth | 2 | 2018 | 5 | 0.730 |
Why?
| | Sphingolipids | 2 | 2020 | 18 | 0.730 |
Why?
| | Cell Line | 10 | 2021 | 1045 | 0.720 |
Why?
| | RNA, Viral | 4 | 2022 | 125 | 0.720 |
Why?
| | Matrix Metalloproteinase 9 | 2 | 2018 | 87 | 0.720 |
Why?
| | Antigens, Viral | 4 | 2016 | 43 | 0.680 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2023 | 41 | 0.680 |
Why?
| | Antigens, Bacterial | 1 | 2020 | 54 | 0.670 |
Why?
| | Cell Survival | 6 | 2025 | 602 | 0.670 |
Why?
| | Brain Stem Neoplasms | 1 | 2020 | 7 | 0.670 |
Why?
| | Quorum Sensing | 2 | 2018 | 10 | 0.670 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 111 | 0.660 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2019 | 327 | 0.660 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2020 | 71 | 0.650 |
Why?
| | Tumor Virus Infections | 1 | 2019 | 48 | 0.650 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 4 | 0.640 |
Why?
| | Hepatocyte Growth Factor | 2 | 2016 | 11 | 0.630 |
Why?
| | Male | 27 | 2024 | 26696 | 0.620 |
Why?
| | Helminth Proteins | 1 | 2018 | 2 | 0.600 |
Why?
| | Antibodies, Antinuclear | 1 | 2018 | 14 | 0.600 |
Why?
| | Antibodies, Protozoan | 1 | 2018 | 11 | 0.600 |
Why?
| | Up-Regulation | 8 | 2020 | 462 | 0.600 |
Why?
| | Middle Aged | 19 | 2024 | 13014 | 0.600 |
Why?
| | 4-Butyrolactone | 1 | 2018 | 5 | 0.600 |
Why?
| | Interleukin-12 | 1 | 2018 | 27 | 0.590 |
Why?
| | Interleukin-17 | 1 | 2018 | 35 | 0.590 |
Why?
| | Endothelium, Vascular | 3 | 2016 | 261 | 0.590 |
Why?
| | Mycobacterium tuberculosis | 1 | 2020 | 291 | 0.590 |
Why?
| | Protein Kinase Inhibitors | 3 | 2018 | 230 | 0.580 |
Why?
| | Fibroblasts | 4 | 2016 | 359 | 0.580 |
Why?
| | Tumor Cells, Cultured | 5 | 2020 | 456 | 0.580 |
Why?
| | Anti-Bacterial Agents | 8 | 2024 | 801 | 0.580 |
Why?
| | Hyaluronic Acid | 2 | 2015 | 38 | 0.570 |
Why?
| | Transcriptional Activation | 1 | 2018 | 128 | 0.570 |
Why?
| | Cells, Cultured | 5 | 2025 | 1589 | 0.560 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2017 | 32 | 0.550 |
Why?
| | Drowning | 3 | 2023 | 6 | 0.540 |
Why?
| | Oncogene Proteins, Viral | 1 | 2017 | 54 | 0.540 |
Why?
| | Diatoms | 3 | 2023 | 24 | 0.530 |
Why?
| | Female | 25 | 2024 | 28105 | 0.530 |
Why?
| | Mice, SCID | 5 | 2020 | 182 | 0.530 |
Why?
| | Herpesvirus 4, Human | 3 | 2022 | 44 | 0.520 |
Why?
| | Trans-Activators | 2 | 2020 | 138 | 0.520 |
Why?
| | Lipid Metabolism | 1 | 2017 | 188 | 0.520 |
Why?
| | Protein Kinases | 2 | 2007 | 74 | 0.510 |
Why?
| | Heme Oxygenase-1 | 1 | 2016 | 18 | 0.510 |
Why?
| | Repressor Proteins | 1 | 2017 | 156 | 0.500 |
Why?
| | ADAM Proteins | 1 | 2016 | 21 | 0.500 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2019 | 58 | 0.500 |
Why?
| | Cell Transformation, Neoplastic | 4 | 2023 | 184 | 0.480 |
Why?
| | Lung | 6 | 2023 | 502 | 0.480 |
Why?
| | Piperidines | 1 | 2015 | 97 | 0.460 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 54 | 0.460 |
Why?
| | Teichoic Acids | 1 | 2014 | 6 | 0.450 |
Why?
| | Virus Internalization | 1 | 2014 | 20 | 0.450 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 77 | 0.450 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2014 | 16 | 0.440 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2013 | 187 | 0.440 |
Why?
| | Cell Cycle Checkpoints | 3 | 2020 | 32 | 0.430 |
Why?
| | Endothelial Cells | 4 | 2024 | 283 | 0.430 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 583 | 0.420 |
Why?
| | Mice, Inbred NOD | 4 | 2020 | 92 | 0.420 |
Why?
| | Carcinoma, Renal Cell | 3 | 2020 | 111 | 0.420 |
Why?
| | Mice, Nude | 6 | 2020 | 236 | 0.420 |
Why?
| | Disease Models, Animal | 5 | 2025 | 1484 | 0.420 |
Why?
| | Adult | 14 | 2024 | 14139 | 0.410 |
Why?
| | Lipopolysaccharides | 1 | 2014 | 207 | 0.400 |
Why?
| | Dual Specificity Phosphatase 1 | 1 | 2012 | 10 | 0.400 |
Why?
| | Staphylococcus aureus | 4 | 2020 | 331 | 0.390 |
Why?
| | Catheters, Indwelling | 1 | 2012 | 57 | 0.380 |
Why?
| | Young Adult | 6 | 2024 | 4319 | 0.380 |
Why?
| | Receptors, Histamine | 2 | 2023 | 7 | 0.370 |
Why?
| | RNA, Messenger | 5 | 2017 | 1142 | 0.370 |
Why?
| | Aged | 12 | 2024 | 10109 | 0.370 |
Why?
| | Neoplasm Invasiveness | 5 | 2019 | 278 | 0.370 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2011 | 4 | 0.360 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 173 | 0.350 |
Why?
| | Mitogen-Activated Protein Kinases | 2 | 2011 | 155 | 0.340 |
Why?
| | Monocytes | 2 | 2017 | 130 | 0.340 |
Why?
| | Interferons | 2 | 2023 | 38 | 0.330 |
Why?
| | Macrophages | 2 | 2010 | 378 | 0.330 |
Why?
| | CCAAT-Enhancer-Binding Protein-beta | 1 | 2010 | 5 | 0.330 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 38 | 0.330 |
Why?
| | Cell Movement | 5 | 2020 | 277 | 0.330 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2010 | 56 | 0.330 |
Why?
| | RNA Interference | 5 | 2016 | 186 | 0.320 |
Why?
| | Immunoblotting | 3 | 2015 | 119 | 0.320 |
Why?
| | China | 9 | 2025 | 134 | 0.320 |
Why?
| | Blotting, Western | 3 | 2017 | 596 | 0.310 |
Why?
| | Disease Progression | 5 | 2021 | 870 | 0.310 |
Why?
| | Transcriptome | 2 | 2025 | 367 | 0.310 |
Why?
| | Down-Regulation | 3 | 2017 | 347 | 0.300 |
Why?
| | Sensitivity and Specificity | 4 | 2025 | 879 | 0.300 |
Why?
| | Staphylococcal Infections | 5 | 2014 | 280 | 0.300 |
Why?
| | Interleukin-6 | 1 | 2010 | 278 | 0.290 |
Why?
| | Cytokines | 4 | 2023 | 625 | 0.290 |
Why?
| | Fluorescent Antibody Technique | 3 | 2015 | 111 | 0.280 |
Why?
| | Hypertension | 2 | 2024 | 565 | 0.280 |
Why?
| | N-Acetylmuramoyl-L-alanine Amidase | 1 | 2007 | 2 | 0.280 |
Why?
| | HIV | 2 | 2019 | 25 | 0.280 |
Why?
| | Adhesins, Bacterial | 1 | 2007 | 28 | 0.270 |
Why?
| | RNA, Small Interfering | 3 | 2016 | 218 | 0.270 |
Why?
| | DNA, Bacterial | 5 | 2014 | 176 | 0.270 |
Why?
| | Coagulase | 1 | 2007 | 3 | 0.270 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2017 | 186 | 0.270 |
Why?
| | Transcription Factors | 2 | 2023 | 574 | 0.270 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 1377 | 0.260 |
Why?
| | Virulence Factors | 2 | 2020 | 80 | 0.250 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 132 | 0.250 |
Why?
| | Schistosoma haematobium | 1 | 2025 | 2 | 0.240 |
Why?
| | Disease Eradication | 1 | 2025 | 1 | 0.240 |
Why?
| | Bulinus | 1 | 2025 | 2 | 0.240 |
Why?
| | Structure-Activity Relationship | 3 | 2020 | 406 | 0.240 |
Why?
| | International Cooperation | 1 | 2025 | 49 | 0.240 |
Why?
| | Heat-Shock Response | 1 | 2025 | 29 | 0.240 |
Why?
| | Oxidative Stress | 1 | 2010 | 810 | 0.230 |
Why?
| | Interferon-gamma | 2 | 2023 | 179 | 0.230 |
Why?
| | Endocytosis | 1 | 2025 | 55 | 0.230 |
Why?
| | Polymerase Chain Reaction | 4 | 2015 | 460 | 0.230 |
Why?
| | Pneumonia | 2 | 2024 | 125 | 0.230 |
Why?
| | Oncogene Proteins | 1 | 2024 | 19 | 0.220 |
Why?
| | Endothelium, Lymphatic | 1 | 2024 | 8 | 0.220 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 44 | 0.220 |
Why?
| | MAP Kinase Signaling System | 2 | 2015 | 127 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2015 | 412 | 0.220 |
Why?
| | Forensic Pathology | 2 | 2021 | 10 | 0.220 |
Why?
| | Molecular Structure | 2 | 2020 | 315 | 0.220 |
Why?
| | Stress, Physiological | 1 | 2025 | 186 | 0.220 |
Why?
| | Azo Compounds | 1 | 2023 | 11 | 0.220 |
Why?
| | Embolism, Fat | 1 | 2023 | 3 | 0.220 |
Why?
| | Phosphorylation | 2 | 2017 | 531 | 0.220 |
Why?
| | DNA Damage | 2 | 2016 | 307 | 0.220 |
Why?
| | Immunocompromised Host | 2 | 2015 | 123 | 0.210 |
Why?
| | Severity of Illness Index | 2 | 2025 | 1021 | 0.210 |
Why?
| | Autoantigens | 1 | 2023 | 53 | 0.210 |
Why?
| | Immunohistochemistry | 2 | 2021 | 985 | 0.210 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2023 | 19 | 0.210 |
Why?
| | Genetic Predisposition to Disease | 4 | 2021 | 528 | 0.210 |
Why?
| | RNA, Bacterial | 2 | 2013 | 55 | 0.200 |
Why?
| | Interferon-alpha | 1 | 2023 | 52 | 0.200 |
Why?
| | Drug Resistance, Bacterial | 2 | 2014 | 81 | 0.200 |
Why?
| | DNA Repair | 1 | 2024 | 195 | 0.200 |
Why?
| | Pulmonary Embolism | 1 | 2023 | 84 | 0.200 |
Why?
| | Ultrasonography, Interventional | 1 | 2023 | 138 | 0.200 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2023 | 58 | 0.200 |
Why?
| | Tubercidin | 1 | 2022 | 3 | 0.190 |
Why?
| | Amaryllidaceae Alkaloids | 1 | 2022 | 3 | 0.190 |
Why?
| | Phenanthridines | 1 | 2022 | 4 | 0.190 |
Why?
| | Gene Expression | 1 | 2025 | 623 | 0.190 |
Why?
| | Transaminases | 1 | 2022 | 11 | 0.190 |
Why?
| | Adenosine Monophosphate | 1 | 2022 | 13 | 0.190 |
Why?
| | beta-Lactamases | 2 | 2012 | 17 | 0.190 |
Why?
| | Cell Cycle | 1 | 2023 | 240 | 0.190 |
Why?
| | Alanine | 1 | 2022 | 44 | 0.190 |
Why?
| | Sex Determination by Skeleton | 1 | 2021 | 1 | 0.190 |
Why?
| | Lymph Nodes | 1 | 2023 | 252 | 0.180 |
Why?
| | Benzamidines | 1 | 2021 | 5 | 0.180 |
Why?
| | Amino Acid Sequence | 2 | 2017 | 591 | 0.180 |
Why?
| | Azithromycin | 1 | 2021 | 26 | 0.180 |
Why?
| | Transfection | 2 | 2014 | 372 | 0.180 |
Why?
| | Guanidines | 1 | 2021 | 29 | 0.180 |
Why?
| | HEK293 Cells | 2 | 2019 | 232 | 0.180 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 87 | 0.180 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 19 | 0.180 |
Why?
| | Immune Evasion | 1 | 2021 | 15 | 0.180 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2021 | 58 | 0.170 |
Why?
| | Disease Susceptibility | 1 | 2021 | 96 | 0.170 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2021 | 84 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2023 | 165 | 0.170 |
Why?
| | Bacteroidaceae Infections | 1 | 2020 | 4 | 0.170 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 150 | 0.170 |
Why?
| | Ubiquitin | 1 | 2020 | 68 | 0.170 |
Why?
| | Vitamin D Deficiency | 1 | 2020 | 45 | 0.170 |
Why?
| | Bacterial Adhesion | 2 | 2012 | 16 | 0.170 |
Why?
| | Glycopyrrolate | 1 | 2020 | 5 | 0.170 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2020 | 5 | 0.170 |
Why?
| | Immunotherapy | 1 | 2022 | 244 | 0.160 |
Why?
| | Muscarinic Antagonists | 1 | 2020 | 25 | 0.160 |
Why?
| | Snails | 1 | 2019 | 4 | 0.160 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 236 | 0.160 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 136 | 0.160 |
Why?
| | Metered Dose Inhalers | 1 | 2020 | 18 | 0.160 |
Why?
| | Survival Rate | 2 | 2021 | 940 | 0.160 |
Why?
| | Genotype | 5 | 2018 | 569 | 0.160 |
Why?
| | Tumor Escape | 1 | 2019 | 17 | 0.160 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2019 | 143 | 0.160 |
Why?
| | Homeodomain Proteins | 1 | 2019 | 81 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 2020 | 181 | 0.150 |
Why?
| | Interleukin-1beta | 1 | 2019 | 86 | 0.150 |
Why?
| | Pneumonia, Bacterial | 2 | 2024 | 30 | 0.150 |
Why?
| | Receptors, Prostaglandin | 1 | 2018 | 4 | 0.150 |
Why?
| | Protein Binding | 4 | 2020 | 680 | 0.150 |
Why?
| | Bacterial Load | 1 | 2018 | 12 | 0.150 |
Why?
| | Autoimmunity | 1 | 2018 | 34 | 0.150 |
Why?
| | Th2 Cells | 1 | 2018 | 23 | 0.150 |
Why?
| | Transplantation, Heterologous | 2 | 2019 | 79 | 0.150 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2018 | 11 | 0.150 |
Why?
| | Receptors, Immunologic | 1 | 2018 | 37 | 0.150 |
Why?
| | Neovascularization, Pathologic | 1 | 2019 | 158 | 0.150 |
Why?
| | Cell Growth Processes | 1 | 2018 | 24 | 0.140 |
Why?
| | Pseudomonas Infections | 1 | 2018 | 54 | 0.140 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 172 | 0.140 |
Why?
| | Virulence | 1 | 2018 | 167 | 0.140 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2017 | 32 | 0.140 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2017 | 15 | 0.140 |
Why?
| | Microscopy, Electron | 1 | 2017 | 74 | 0.140 |
Why?
| | Databases, Factual | 1 | 2021 | 706 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2020 | 146 | 0.140 |
Why?
| | Pandemics | 1 | 2022 | 585 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2018 | 124 | 0.140 |
Why?
| | Annexin A5 | 1 | 2017 | 14 | 0.140 |
Why?
| | Sphingosine | 2 | 2015 | 34 | 0.140 |
Why?
| | Random Allocation | 1 | 2018 | 287 | 0.130 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2017 | 58 | 0.130 |
Why?
| | Image-Guided Biopsy | 1 | 2017 | 34 | 0.130 |
Why?
| | Toll-Like Receptor 2 | 1 | 2017 | 24 | 0.130 |
Why?
| | Immunoglobulin G | 1 | 2017 | 195 | 0.130 |
Why?
| | Lysophospholipids | 2 | 2015 | 70 | 0.130 |
Why?
| | Hypertension, Pulmonary | 1 | 2018 | 118 | 0.130 |
Why?
| | Exons | 1 | 2017 | 102 | 0.130 |
Why?
| | Glutathione S-Transferase pi | 1 | 2016 | 25 | 0.130 |
Why?
| | Exoribonucleases | 1 | 2016 | 2 | 0.130 |
Why?
| | Exonucleases | 1 | 2016 | 5 | 0.130 |
Why?
| | Toll-Like Receptor 4 | 1 | 2017 | 50 | 0.130 |
Why?
| | Vancomycin | 2 | 2007 | 85 | 0.130 |
Why?
| | Pleural Effusion | 1 | 2017 | 38 | 0.130 |
Why?
| | Ubiquitins | 1 | 2016 | 40 | 0.130 |
Why?
| | Aptamers, Nucleotide | 1 | 2016 | 8 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 113 | 0.130 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2017 | 111 | 0.130 |
Why?
| | Protoporphyrins | 1 | 2016 | 5 | 0.130 |
Why?
| | Metalloporphyrins | 1 | 2016 | 6 | 0.130 |
Why?
| | Molluscacides | 1 | 2015 | 1 | 0.120 |
Why?
| | Salicylanilides | 1 | 2015 | 1 | 0.120 |
Why?
| | Gastropoda | 1 | 2015 | 3 | 0.120 |
Why?
| | Comet Assay | 1 | 2015 | 11 | 0.120 |
Why?
| | Base Sequence | 1 | 2017 | 648 | 0.120 |
Why?
| | Glutathione Transferase | 1 | 2016 | 176 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2018 | 340 | 0.120 |
Why?
| | Anthelmintics | 1 | 2015 | 12 | 0.120 |
Why?
| | Autophagy | 1 | 2017 | 197 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 179 | 0.120 |
Why?
| | Necrosis | 1 | 2016 | 173 | 0.120 |
Why?
| | Algorithms | 1 | 2019 | 668 | 0.120 |
Why?
| | Oxidoreductases | 1 | 2015 | 59 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2024 | 3391 | 0.120 |
Why?
| | Nerve Tissue Proteins | 1 | 2017 | 193 | 0.120 |
Why?
| | Cohort Studies | 1 | 2019 | 1532 | 0.120 |
Why?
| | Virginiamycin | 1 | 2014 | 1 | 0.110 |
Why?
| | Pyrazoles | 1 | 2015 | 114 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2020 | 312 | 0.110 |
Why?
| | Glutamates | 1 | 2014 | 21 | 0.110 |
Why?
| | Cystine | 1 | 2014 | 11 | 0.110 |
Why?
| | Glucuronosyltransferase | 1 | 2015 | 122 | 0.110 |
Why?
| | Lymphocytes | 2 | 2017 | 150 | 0.110 |
Why?
| | Leukocidins | 1 | 2013 | 7 | 0.110 |
Why?
| | Exotoxins | 1 | 2013 | 8 | 0.110 |
Why?
| | Flow Cytometry | 1 | 2015 | 404 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1031 | 0.110 |
Why?
| | Bacterial Toxins | 1 | 2013 | 51 | 0.110 |
Why?
| | Models, Biological | 2 | 2007 | 743 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 3 | 2012 | 286 | 0.100 |
Why?
| | Prostatic Neoplasms | 1 | 2017 | 400 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 2 | 2024 | 35 | 0.100 |
Why?
| | Sodium | 2 | 2024 | 94 | 0.100 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2013 | 80 | 0.100 |
Why?
| | Bacteriolysis | 1 | 2012 | 3 | 0.100 |
Why?
| | NF-kappa B | 1 | 2014 | 328 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2013 | 134 | 0.100 |
Why?
| | Child | 3 | 2025 | 7157 | 0.100 |
Why?
| | Klebsiella Infections | 1 | 2012 | 13 | 0.100 |
Why?
| | Klebsiella pneumoniae | 1 | 2012 | 20 | 0.100 |
Why?
| | Reactive Oxygen Species | 1 | 2014 | 425 | 0.100 |
Why?
| | beta-Lactams | 1 | 2011 | 31 | 0.090 |
Why?
| | Mouth Neoplasms | 1 | 2011 | 22 | 0.090 |
Why?
| | Cross Infection | 1 | 2012 | 93 | 0.090 |
Why?
| | Salmonella enterica | 1 | 2011 | 17 | 0.090 |
Why?
| | Bacteremia | 1 | 2012 | 90 | 0.090 |
Why?
| | Disease Outbreaks | 1 | 2012 | 123 | 0.090 |
Why?
| | Mutation | 2 | 2020 | 1351 | 0.090 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 186 | 0.090 |
Why?
| | Cytopathogenic Effect, Viral | 1 | 2010 | 5 | 0.090 |
Why?
| | Colony-Forming Units Assay | 1 | 2010 | 23 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2024 | 713 | 0.080 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2010 | 10 | 0.080 |
Why?
| | Reactive Nitrogen Species | 1 | 2010 | 23 | 0.080 |
Why?
| | Cell Adhesion | 1 | 2010 | 164 | 0.080 |
Why?
| | 3' Untranslated Regions | 1 | 2010 | 55 | 0.080 |
Why?
| | Protein Isoforms | 1 | 2010 | 126 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2024 | 909 | 0.080 |
Why?
| | Polysaccharide-Lyases | 1 | 2009 | 7 | 0.080 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2009 | 7 | 0.080 |
Why?
| | Colony Count, Microbial | 1 | 2009 | 61 | 0.080 |
Why?
| | Adolescent | 2 | 2018 | 6692 | 0.080 |
Why?
| | Molecular Typing | 3 | 2014 | 11 | 0.080 |
Why?
| | Neoplasm Metastasis | 2 | 2020 | 240 | 0.080 |
Why?
| | Polysaccharides, Bacterial | 1 | 2009 | 16 | 0.080 |
Why?
| | Prognosis | 3 | 2021 | 2094 | 0.080 |
Why?
| | Case-Control Studies | 2 | 2022 | 1201 | 0.070 |
Why?
| | Bacteriological Techniques | 1 | 2007 | 41 | 0.070 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 84 | 0.070 |
Why?
| | Neoplasm Staging | 1 | 2010 | 770 | 0.070 |
Why?
| | Lysostaphin | 1 | 2007 | 2 | 0.070 |
Why?
| | Microbial Viability | 1 | 2007 | 32 | 0.070 |
Why?
| | Genetic Heterogeneity | 1 | 2007 | 20 | 0.070 |
Why?
| | Vero Cells | 1 | 2006 | 44 | 0.070 |
Why?
| | Hemolysis | 1 | 2006 | 28 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 71 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2006 | 145 | 0.060 |
Why?
| | Species Specificity | 1 | 2007 | 192 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 252 | 0.060 |
Why?
| | Liver | 2 | 2023 | 1159 | 0.060 |
Why?
| | Binding Sites | 1 | 2006 | 379 | 0.060 |
Why?
| | Zimbabwe | 1 | 2025 | 3 | 0.060 |
Why?
| | Schistosomiasis haematobia | 1 | 2025 | 3 | 0.060 |
Why?
| | Molecular Sequence Annotation | 1 | 2025 | 28 | 0.060 |
Why?
| | Host-Parasite Interactions | 1 | 2025 | 15 | 0.060 |
Why?
| | Models, Molecular | 1 | 2006 | 352 | 0.060 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 792 | 0.060 |
Why?
| | Prodrugs | 1 | 2025 | 35 | 0.060 |
Why?
| | Endosomes | 1 | 2025 | 36 | 0.060 |
Why?
| | Proteolysis | 1 | 2025 | 102 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 429 | 0.060 |
Why?
| | Temperature | 1 | 2025 | 165 | 0.060 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2024 | 6 | 0.050 |
Why?
| | Administration, Intravenous | 1 | 2024 | 73 | 0.050 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2023 | 6 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2024 | 220 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2017 | 150 | 0.050 |
Why?
| | Genes, Bacterial | 2 | 2014 | 52 | 0.050 |
Why?
| | Staining and Labeling | 1 | 2023 | 92 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2025 | 402 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 44 | 0.050 |
Why?
| | Receptors, Interleukin-1 | 1 | 2022 | 18 | 0.050 |
Why?
| | Adenosine Triphosphate | 1 | 2024 | 208 | 0.050 |
Why?
| | Carbon | 1 | 2023 | 55 | 0.050 |
Why?
| | Pilot Projects | 1 | 2025 | 719 | 0.050 |
Why?
| | Adaptive Immunity | 1 | 2022 | 33 | 0.050 |
Why?
| | Molecular Epidemiology | 2 | 2012 | 38 | 0.050 |
Why?
| | Sodium Chloride Symporters | 1 | 2022 | 7 | 0.050 |
Why?
| | Kidney Tubules, Distal | 1 | 2022 | 15 | 0.050 |
Why?
| | Fibrosis | 1 | 2023 | 197 | 0.050 |
Why?
| | Pubic Bone | 1 | 2021 | 6 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2024 | 5407 | 0.050 |
Why?
| | Risk Factors | 2 | 2022 | 3872 | 0.050 |
Why?
| | Neglected Diseases | 1 | 2021 | 2 | 0.040 |
Why?
| | Pelvis | 1 | 2021 | 69 | 0.040 |
Why?
| | Rivers | 1 | 2021 | 9 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2021 | 117 | 0.040 |
Why?
| | Neovascularization, Physiologic | 1 | 2021 | 86 | 0.040 |
Why?
| | Seasons | 1 | 2021 | 91 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2023 | 241 | 0.040 |
Why?
| | Genome, Viral | 1 | 2020 | 83 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2021 | 121 | 0.040 |
Why?
| | Vitamin D | 1 | 2020 | 89 | 0.040 |
Why?
| | Models, Animal | 1 | 2021 | 228 | 0.040 |
Why?
| | Spleen | 1 | 2021 | 173 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2021 | 443 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2020 | 52 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 1676 | 0.040 |
Why?
| | Phenotype | 2 | 2014 | 799 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 134 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2020 | 115 | 0.040 |
Why?
| | Vimentin | 1 | 2019 | 32 | 0.040 |
Why?
| | Wnt3A Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Artificial Intelligence | 1 | 2021 | 115 | 0.040 |
Why?
| | Cadherins | 1 | 2019 | 63 | 0.040 |
Why?
| | Recovery of Function | 1 | 2020 | 200 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2020 | 77 | 0.040 |
Why?
| | Chimera | 1 | 2018 | 10 | 0.040 |
Why?
| | Ovalbumin | 1 | 2018 | 19 | 0.040 |
Why?
| | STAT6 Transcription Factor | 1 | 2018 | 9 | 0.040 |
Why?
| | Adoptive Transfer | 1 | 2018 | 29 | 0.040 |
Why?
| | beta Catenin | 1 | 2019 | 103 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 474 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2024 | 1903 | 0.040 |
Why?
| | Immunity | 1 | 2018 | 39 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 95 | 0.040 |
Why?
| | Pyrroles | 1 | 2018 | 71 | 0.040 |
Why?
| | Antibodies | 1 | 2018 | 152 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 2017 | 33 | 0.040 |
Why?
| | Oxygen | 1 | 2020 | 336 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2017 | 58 | 0.040 |
Why?
| | Oncogene Protein v-akt | 1 | 2017 | 12 | 0.030 |
Why?
| | Alleles | 1 | 2018 | 277 | 0.030 |
Why?
| | Perineum | 1 | 2017 | 26 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 276 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 2021 | 1552 | 0.030 |
Why?
| | Rectum | 1 | 2017 | 55 | 0.030 |
Why?
| | Isoenzymes | 1 | 2017 | 167 | 0.030 |
Why?
| | Killer Cells, Natural | 1 | 2017 | 116 | 0.030 |
Why?
| | Pulmonary Artery | 1 | 2018 | 146 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 82 | 0.030 |
Why?
| | Polymorphism, Genetic | 1 | 2017 | 185 | 0.030 |
Why?
| | SELEX Aptamer Technique | 1 | 2016 | 1 | 0.030 |
Why?
| | Zygote | 1 | 2016 | 10 | 0.030 |
Why?
| | Bone Marrow | 1 | 2018 | 364 | 0.030 |
Why?
| | Parasitic Sensitivity Tests | 1 | 2015 | 1 | 0.030 |
Why?
| | Niclosamide | 1 | 2015 | 2 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2021 | 1162 | 0.030 |
Why?
| | Acetylcholinesterase | 1 | 2015 | 20 | 0.030 |
Why?
| | Esters | 1 | 2015 | 19 | 0.030 |
Why?
| | Chronic Disease | 1 | 2018 | 583 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2015 | 71 | 0.030 |
Why?
| | Blood Pressure | 1 | 2018 | 534 | 0.030 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 74 | 0.030 |
Why?
| | Indoles | 1 | 2018 | 278 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 2015 | 64 | 0.030 |
Why?
| | Zebrafish | 1 | 2015 | 60 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 506 | 0.030 |
Why?
| | Rats | 1 | 2021 | 3202 | 0.030 |
Why?
| | Primary Cell Culture | 1 | 2014 | 62 | 0.030 |
Why?
| | Monocarboxylic Acid Transporters | 1 | 2014 | 2 | 0.030 |
Why?
| | Membrane Microdomains | 1 | 2014 | 12 | 0.030 |
Why?
| | Child, Preschool | 2 | 2013 | 4030 | 0.030 |
Why?
| | Iatrogenic Disease | 1 | 2013 | 25 | 0.030 |
Why?
| | Vesicular Transport Proteins | 1 | 2014 | 38 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2014 | 230 | 0.030 |
Why?
| | Time Factors | 1 | 2020 | 2957 | 0.030 |
Why?
| | Mass Screening | 1 | 2016 | 357 | 0.030 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2012 | 28 | 0.020 |
Why?
| | Intensive Care, Neonatal | 1 | 2012 | 23 | 0.020 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2012 | 70 | 0.020 |
Why?
| | Salmonella Infections | 1 | 2011 | 17 | 0.020 |
Why?
| | Plasmids | 1 | 2012 | 167 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 232 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2011 | 180 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 272 | 0.020 |
Why?
| | Hospitals | 1 | 2012 | 181 | 0.020 |
Why?
| | Feces | 1 | 2011 | 154 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2011 | 172 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2016 | 2268 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2012 | 2826 | 0.010 |
Why?
|
|
Qin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|